How does mismatch repair deficiency affect Ovarian Cancer treatment

Mismatch Repair Deficiency and Ovarian Cancer Treatment

I'll explain how mismatch repair deficiency (a DNA repair problem) affects your treatment options for ovarian cancer.

What is Mismatch Repair Deficiency?

Mismatch repair (MMR) is your cells' quality-control system for DNA. Think of it like a proofreader checking for typos in a document. When this system doesn't work properly (called "deficiency" or dMMR), errors in DNA accumulate, creating a pattern called microsatellite instability (MSI).

According to the NCCN Guidelines for Ovarian Cancer, testing for mismatch repair deficiency is an important part of understanding your tumor's characteristics and determining which treatments might work best for you.

How This Affects Treatment Decisions

1. Immunotherapy Response

When mismatch repair is deficient, cancer cells accumulate many mutations (DNA changes). This is actually beneficial for immunotherapy because:

• These mutations make cancer cells look "different" to your immune system
• Your immune system can recognize these abnormal cells more easily
• Checkpoint inhibitor drugs (like pembrolizumab/Keytruda) work better when there are more mutations to target

According to cancer immunotherapy research, MSI-high tumors show better response rates to immune checkpoint inhibitors because the immune system has more "targets" to recognize.

2. PARP Inhibitor Eligibility

According to NCCN Guidelines, mismatch repair status helps determine eligibility for PARP inhibitors (drugs like olaparib, niraparib, and rucaparib), which are maintenance therapies used after chemotherapy. These drugs work particularly well in patients with:

• BRCA mutations
• Homologous recombination deficiency (HRD)
• Certain mismatch repair patterns

3. Chemotherapy Sensitivity

Tumors with mismatch repair deficiency may respond differently to platinum-based chemotherapy (like carboplatin), which is standard first-line treatment for ovarian cancer.

Why Testing Matters

According to NCCN Ovarian Cancer Guidelines, molecular testing should include evaluation of:

• Mismatch repair (MMR) status
• Microsatellite instability (MSI)
• Other DNA repair pathway genes

This testing is typically done on your tumor tissue using immunohistochemistry (IHC) or molecular profiling in a CLIA-approved laboratory.

Questions to Ask Your Oncology Team

1. Has my tumor been tested for mismatch repair deficiency and microsatellite instability?
2. If I have MMR deficiency, what does this mean for my specific treatment plan?
3. Am I eligible for immunotherapy based on my MMR status?
4. How does my MMR status affect my eligibility for PARP inhibitors or other targeted therapies?
5. Should this testing be repeated if my cancer recurs?

Important Context

The NCCN Guidelines recommend that tumor molecular analysis be performed both at initial diagnosis and at the time of recurrence, because new mutations can develop as cancer evolves. If your cancer progresses, your doctor may recommend repeat testing to identify new treatment opportunities.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.